乙醇与中枢神经系统抑制剂娱乐性药物合用急性中毒的临床效应
该研究为回顾性多中心研究,使用Euro-DEN Plus数据库2014年1月至2019年12月数据,纳入43 633例次就诊中的7 644例(17.5%)中枢神经系统抑制剂药物急性中毒患者,其中3 811例(49.9%)同时摄入乙醇。比较有无乙醇合用者的流行病学与临床特征及急诊和住院管理。乙醇合用组更常见GCS≤8(34.1% vs. 22.4%;P < 0.001)、呕吐(8.1% vs. 4.6%;P < 0.001)、焦虑(12% vs. 6.4%;P < 0.001)、激越/攻击(22% vs. 14.7%;P < 0.001)、癫痫发作(3.8% vs. 2.4%;P < 0.001)和低血压(7.5% vs. 4.6%;P < 0.001),更多需要救护车转运(85.5% vs. 76.5%;P < 0.001)、医疗处理(57.3% vs. 48.0%;P < 0.001)、住院(27.7% vs. 18.9%;P < 0.001)和入住ICU(12.2% vs. 4.0%;P < 0.001)。亚组分析显示GCS≤8在乙醇与阿片类或γ-羟基丁酸(GHB)/γ-丁内酯(GBL)合用时尤为常见。
要点
- 在涉及中枢神经系统抑制剂娱乐性药物的急性中毒患者中,乙醇合用率为49.9%(3811/7644),合用者GCS≤8比例更高(34.1% vs. 22.4%;P < 0.001)。
- 乙醇合用者呕吐(8.1% vs. 4.6%)、焦虑(12% vs. 6.4%)、激越/攻击(22% vs. 14.7%)、癫痫发作(3.8% vs. 2.4%)和低血压(7.5% vs. 4.6%)均更常见,各P < 0.001。
- 乙醇合用者更多需要救护车转运(85.5% vs. 76.5%)、医疗处理(57.3% vs. 48.0%)、住院(27.7% vs. 18.9%)和入住ICU(12.2% vs. 4.0%),各P < 0.001。
- 亚组分析显示,GCS≤8在乙醇与阿片类或GHB/GBL合用时尤为常见。
- 总体53.3%需要医疗处理,14例死亡。
适用人群与场景
- 2014年1月至2019年12月期间到急诊科就诊、涉及中枢神经系统抑制剂娱乐性药物急性中毒的患者(Euro-DEN Plus数据库)。
红旗征与不能漏的情况
- 乙醇与中枢神经系统抑制剂合用者更常见GCS≤8(34.1% vs. 22.4%;P < 0.001),尤其与阿片类或GHB/GBL合用时GCS≤8尤为常见。
- 乙醇合用者更常见呕吐(8.1% vs. 4.6%;P < 0.001)、焦虑(12% vs. 6.4%;P < 0.001)、激越/攻击(22% vs. 14.7%;P < 0.001)、癫痫发作(3.8% vs. 2.4%;P < 0.001)和低血压(7.5% vs. 4.6%;P < 0.001)。
研究设计与关键结果
- 研究类型:回顾性多中心研究,使用Euro-DEN Plus数据库2014年1月至2019年12月数据。
- 样本量:43 633例次就诊中纳入7 644例(17.5%),其中乙醇合用3 811例(49.9%)。
- 人群:涉及中枢神经系统抑制剂娱乐性药物急性中毒的急诊患者。
- 主要终点:比较有无乙醇合用者的流行病学与临床特征及急诊和住院管理。
- 总体53.3%需要医疗处理,14例死亡。
- 乙醇合用组 vs. 无乙醇合用组:GCS≤8 34.1% vs. 22.4%(P < 0.001);呕吐8.1% vs. 4.6%(P < 0.001);焦虑12% vs. 6.4%(P < 0.001);激越/攻击22% vs. 14.7%(P < 0.001);癫痫发作3.8% vs. 2.4%(P < 0.001);低血压7.5% vs. 4.6%(P < 0.001)。
- 乙醇合用组 vs. 无乙醇合用组:救护车转运85.5% vs. 76.5%(P < 0.001);医疗处理57.3% vs. 48.0%(P < 0.001);住院27.7% vs. 18.9%(P < 0.001);入住ICU 12.2% vs. 4.0%(P < 0.001)。
- 亚组分析:GCS≤8在乙醇与阿片类或GHB/GBL合用时尤为常见。
证据类型、等级与局限
- 证据类型:回顾性多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,乙醇与中枢神经系统抑制剂药物合用似乎增加不良反应风险,并与更高的医疗处理需求相关,尤其当乙醇与阿片类或GHB/GBL合用时。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: Patients who use recreational drugs frequently co-ingest ethanol, which is considered a central nervous system (CNS) depressant. The clinical relevance of this in acute toxicity involving other CNS depressants is not well described.
OBJECTIVE: To assess the clinical impact of ethanol co-use in patients presenting to the emergency department (ED) with acute toxicity involving the use of CNS depressant drugs.
DESIGN, SETTINGS AND PARTICIPANTS: A retrospective multicentre study using data from the Euro-DEN Plus database from January 2014 to December 2019.
OUTCOMES MEASURE AND ANALYSIS: Comparison of epidemiologic and clinical characteristics, ED and hospital management of patients with CNS depressant intoxication with or without ethanol co-use.
MAIN RESULTS: Although 7644 (17.5%) of the 43 633 presentations were included, ethanol was co-ingested in 3811 (49.9%). In total 53.3% required medical treatment, 14 patients died. Patients with ethanol co-use more frequently presented with a Glasgow Coma Scale (GCS) ≤8 (34.1% vs. 22.4%; P < 0.001), vomiting (8.1% vs. 4.6%; P < 0.001), anxiety (12 % vs. 6.4%; P < 0.001), agitation/aggression (22% vs. 14.7%; P < 0.001), seizures (3.8% vs. 2.4%; P < 0.001) and hypotension (7.5% vs. 4.6%; P < 0.001). They more often required ambulance transport (85.5% vs. 76.5%; P < 0.001), medical treatment (57.3% vs. 48.0%; P < 0.001), hospitalization (27.7% vs. 18.9%; P < 0.001), and admission to intensive care (12.2% vs. 4.0%; P < 0.001). Subgroup analysis showed that GCS ≤8 was particularly common in patients who combined ethanol with opioids or gamma-hydroxybutyrate (GHB)/gamma-butyrolactone (GBL).
CONCLUSION: Co-use of ethanol with CNS-depressant drugs appears to increase the risk of adverse effects and is associated with a higher need for medical treatment, especially when ethanol is combined with opioids or GHB/GBL.
参考来源
- Heier EC, Eyer F, Rabe C, et al. Clinical effect of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs. Eur J Emerg Med. 2022. PMID: 35404314. doi:10.1097/MEJ.0000000000000932
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。